- Home
- CTRM vs NXL Comparison
CTRM vs NXL Comparison
Compare CTRM & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- NXL
- Stock Information
- Founded
- CTRM 2016
- NXL 2010
- Country
- CTRM Cyprus
- NXL United States
- Employees
- CTRM N/A
- NXL N/A
- Industry
- CTRM Marine Transportation
- NXL Medical Specialities
- Sector
- CTRM Consumer Discretionary
- NXL Health Care
- Exchange
- CTRM Nasdaq
- NXL Nasdaq
- Market Cap
- CTRM 20.7M
- NXL 24.2M
- IPO Year
- CTRM N/A
- NXL 2022
- Fundamental
- Price
- CTRM $2.32
- NXL $1.19
- Analyst Decision
- CTRM
- NXL Strong Buy
- Analyst Count
- CTRM 0
- NXL 1
- Target Price
- CTRM N/A
- NXL $5.00
- AVG Volume (30 Days)
- CTRM 62.6K
- NXL 91.9K
- Earning Date
- CTRM 06-17-2025
- NXL 05-13-2025
- Dividend Yield
- CTRM N/A
- NXL N/A
- EPS Growth
- CTRM N/A
- NXL N/A
- EPS
- CTRM 0.38
- NXL N/A
- Revenue
- CTRM $66,243,379.00
- NXL $131,065.00
- Revenue This Year
- CTRM N/A
- NXL $79.59
- Revenue Next Year
- CTRM N/A
- NXL $334.65
- P/E Ratio
- CTRM $6.23
- NXL N/A
- Revenue Growth
- CTRM N/A
- NXL N/A
- 52 Week Low
- CTRM $1.98
- NXL $0.53
- 52 Week High
- CTRM $5.49
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- CTRM 54.53
- NXL 34.01
- Support Level
- CTRM $2.30
- NXL $1.18
- Resistance Level
- CTRM $2.44
- NXL $1.29
- Average True Range (ATR)
- CTRM 0.11
- NXL 0.07
- MACD
- CTRM 0.01
- NXL 0.03
- Stochastic Oscillator
- CTRM 52.76
- NXL 10.00
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under two reportable segments namely Dry bulk; Aframax/LR2 tanker; Handysize tanker and Container ship. It generates maximum revenue from the Dry bulk segment.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.